Tyrosine-protein kinase Fes/Fps
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tyrosine-protein kinase Fes/Fps as ChEMBL target CHEMBL5455, mapped to UniProt P07332. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Tyrosine-protein kinase Fes/Fps matters
Tyrosine-protein kinase Fes/Fps is reviewed as Tyrosine-protein kinase Fes/Fps (UniProt P07332); the current evidence base includes 13 approved drugs, 1691 compounds, and 319 assays, with lead potency reaching pChEMBL 9.0.
Tyrosine-protein kinase Fes/Fps Sequence length is 822 aa.
Review this target as Tyrosine-protein kinase Fes/Fps, mapped to UniProt P07332. Sequence length is 822 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 13 approved drugs, 1691 compounds, and 319 assays for this target. The dominant activity type is KI. CHEMBL459850 is the current potency anchor at pChEMBL 9.0.
Use CHEMBL459850 as the tractability anchor when discussing potency (pChEMBL 9.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Tyrosine-protein kinase Fes/Fps matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P07332, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL459850
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL388978
|
8.8 | IC50 | — |
|
|
No preferred name
CHEMBL3545311
|
8.5 | IC50 | Approved |
|
|
No preferred name
CHEMBL509032
|
8.3 | Kd | — |
|
|
No preferred name
CHEMBL4846921
|
8.3 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
LORLATINIB
CHEMBL3286830
|
2018 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
SUNITINIB
CHEMBL535
|
2006 |